🟢 Optimi Health Corp. (OPTH) shares surge 9.6%, continuing momentum after announcing first psilocybin export to the U.K.

Shares of Optimi Health are extending gains after the company announced on June 10 that it had completed its first export of naturally derived psilocybin to the United Kingdom.

• The shipment, which includes psilocybin biomass and 5mg capsules, is intended to support a planned Phase 2 clinical trial.
• This event marks the company's first entry into the U.K. market, positioning it as a key supplier for regulated psychedelic research.
• The move follows other recent positive updates, including securing an Ibogaine supply for drug development on June 8, further fueling investor interest.